Department of Microbiology, Soochow University, Taipei 111, Taiwan.
Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al Kharj 11942, Saudi Arabia.
Biomolecules. 2022 Aug 3;12(8):1072. doi: 10.3390/biom12081072.
Skin inflammation occurs due to immune dysregulation because of internal disorders, infections, and allergic reactions. The inflammation of the skin is a major sign of chronic autoimmune inflammatory diseases, such as psoriasis, atopic dermatitis (AD), and lupus erythematosus. Although there are many therapies for treating these cutaneous inflammation diseases, their recurrence rates are high due to incomplete resolution. MicroRNA (miRNA) plays a critical role in skin inflammation by regulating the expression of protein-coding genes at the posttranscriptional level during pathogenesis and homeostasis maintenance. Some miRNAs possess anti-inflammatory features, which are beneficial for mitigating the inflammatory response. miRNAs that are reduced in inflammatory skin diseases can be supplied transiently using miRNA mimics and agomir. miRNA-based therapies that can target multiple genes in a given pathway are potential candidates for the treatment of skin inflammation. This review article offers an overview of the function of miRNA in skin inflammation regulation, with a focus on psoriasis, AD, and cutaneous wounds. Some bioactive molecules can target and modulate miRNAs to achieve the objective of inflammation suppression. This review also reports the anti-inflammatory efficacy of these molecules through modulating miRNA expression. The main limitations of miRNA-based therapies are rapid biodegradation and poor skin and cell penetration. Consideration was given to improving these drawbacks using the approaches of cell-penetrating peptides (CPPs), nanocarriers, exosomes, and low-frequency ultrasound. A formulation design for successful miRNA delivery into skin and target cells is also described in this review. The possible use of miRNAs as biomarkers and therapeutic modalities could open a novel opportunity for the diagnosis and treatment of inflammation-associated skin diseases.
皮肤炎症是由免疫失调引起的,其原因包括内部紊乱、感染和过敏反应。皮肤炎症是慢性自身免疫性炎症性疾病的主要标志,如银屑病、特应性皮炎 (AD) 和红斑狼疮。尽管有许多治疗方法可用于治疗这些皮肤炎症性疾病,但由于治疗不完全,其复发率很高。microRNA (miRNA) 通过在发病机制和维持内稳态过程中调节蛋白质编码基因的转录后表达,在皮肤炎症中发挥关键作用。一些 miRNA 具有抗炎特性,有利于减轻炎症反应。在炎症性皮肤病中减少的 miRNA 可以使用 miRNA 模拟物和激动剂短暂补充。基于 miRNA 的疗法可以针对给定途径中的多个基因,是治疗皮肤炎症的潜在候选药物。本文综述了 miRNA 在皮肤炎症调控中的作用,重点介绍了银屑病、AD 和皮肤伤口。一些生物活性分子可以靶向和调节 miRNA,以达到抑制炎症的目的。本文还通过调节 miRNA 表达报告了这些分子的抗炎疗效。miRNA 疗法的主要局限性是快速降解和皮肤及细胞穿透性差。考虑使用细胞穿透肽 (CPP)、纳米载体、外泌体和低频超声来改善这些缺点。本文还描述了成功将 miRNA 递送至皮肤和靶细胞的制剂设计。将 miRNA 用作生物标志物和治疗方式的可能性为炎症相关皮肤病的诊断和治疗开辟了新的机会。